Efficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk

Back to Search
Print
Bookmark Trial

NCT00194090

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
University Hospitals of Cleveland
Cleveland, Ohio, 44106, United States
See other locations
Contact
(216) 591-1443
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

(216) 591-1443

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Knee Osteoarthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
45-85 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Knee osteoarthritis by ACR clinical criteria Pain of at least 40 mm by VAS at baseline

-

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Non-pregant, non-lactating Able to stop active arthritis medication for washout
Cardiovascular risk factors Abnormal EKG -

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Knee OsteoarthritisWearable Sensors in Knee OA
NCT04243096
  1. Boston, Massachusetts
ALL GENDERS
50 Years+
years
MULTIPLE SITES
Knee OsteoarthritisEfficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk
NCT00194090
  1. Cleveland, Ohio
ALL GENDERS
45 Years+
years
MULTIPLE SITES
Knee OsteoarthritisA Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)
NCT00650624
  1. Funabashi, Chiba
  2. Sakura, Chiba
  3. Chikushi-gun, Fukuoka
  4. Iizuka, Fukuoka
  5. Kurume, Fukuoka
  6. Yame, Fukuoka
  7. Chitose, Hokkaido
  8. Sapporo, Hokkaido
  9. Kamakura, Kanagawa
  10. Yokohama, Kanagawa
  11. Isahaya, Nagasaki
  12. Hirakata, Osaka
  13. Kanzaki-gun, Saga
  14. Karatsu, Saga
  15. Ogi-gun, Saga
  16. Itabashi-ku, Tokyo
  17. Setagaya-ku, Tokyo
  18. Shinjuku-Ku, Tokyo
  19. Taito-ku, Tokyo
  20. Yoyogi Shibuya-ku, Tokyo
  21. Saga,
  22. Tokyo,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Knee OsteoarthritisEfficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)
NCT00630929
  1. Bad Muender,
  2. Beckum,
  3. Berlin,
  4. Berlin,
  5. Berlin,
  6. Berlin,
  7. Ostseebad Damp,
  8. Schwerin,
  9. Stade,
  10. Tostedt,
  11. Weener,
  12. Barcelona,
  13. Barcelona,
  14. Cadiz,
  15. Guadalajara,
  16. Madrid,
  17. Madrid,
  18. Madrid,
  19. Oviedo,
  20. Sevilla,
  21. Valencia,
  22. Chelmsly Wood, Birmingham
  23. Truro, Cornwall
  24. Chorley, Lancs
  25. Liverpool, Lancs
  26. Cannock, Mid Staffordshire
  27. Addlestone, Surrey
  28. Huddersfield,
  29. London,
  30. London,
  31. Manchester,
  32. Newcastle Upon Tyne,
  33. Wigan,
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Efficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk
Official Title  ICMJE A Double-Blind, Placebo-Controlled, Crossover Pilot Study of the Efficacy of Celecoxib 200 Mg Qd in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee
Brief Summary A paced 20-minute walk is a reproducible model for acute pain in knee osteoarthritis
Detailed Description

This is a randomizd, placbo-controlled, crossover trial comparing a single dose of celecoxib to placebo measuring the time to onset of acute pain in a paced 20-minute walk.

40 subjects will be enrolled

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Knee Osteoarthritis
Intervention  ICMJE Drug: celecoxib
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Enrollment  ICMJE
 (submitted: September 13, 2005)		40
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE September 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

Knee osteoarthritis by ACR clinical criteria Pain of at least 40 mm by VAS at baseline

-

Exclusion Criteria:

Non-pregant, non-lactating Able to stop active arthritis medication for washout Cardiovascular risk factors Abnormal EKG -

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 45 Years to 85 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00194090
Other Study ID Numbers  ICMJE 06-04-41
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE University Hospitals Cleveland Medical Center
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Michele M Hooper, MD, MSUniversity Hospitals Cleveland Medical Center
PRS Account University Hospitals Cleveland Medical Center
Verification Date July 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP